Theravance Biopharma to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
(firmenpresse) - DUBLIN, IRELAND -- (Marketwired) -- 07/06/16 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that Brett Haumann, Senior Vice President, Clinical Development and Chief Medical Officer, will present a corporate overview at the upcoming Cantor Fitzgerald 2nd Annual Healthcare Conference on Wednesday, July 13, 2016 at 10:15 a.m. ET. The conference will be held from July 12-13 in New York at the Le Parker Meridien Hotel.
A live broadcast of the presentation will be available by visiting the Investor Relations section of Theravance Biopharma's website at , under the Presentations & Events tab. Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software.
Theravance Biopharma is a diversified biopharmaceutical company with the core purpose of creating medicines that make a difference in the lives of patients suffering from serious illness. Our pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease (COPD). Our neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of major cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases such as diabetic nephropathy. Our research efforts are focused in the areas of inflammation and immunology, with the goal of designing medicines that provide targeted drug delivery to tissues in the lung and gastrointestinal tract in order to maximize patient benefit and minimize risk. The first program to emerge from this research is designed to develop GI-targeted pan-Janus kinase (JAK) inhibitors for the treatment of a range of inflammatory intestinal diseases.
In addition, we have an economic interest in future payments that may be made by Glaxo Group Limited or one of its affiliates pursuant to its agreements with Innoviva, Inc. relating to certain drug development programs, including the Closed Triple (the combination of fluticasone furoate, umeclidinium, and vilanterol), currently in development for the treatment of COPD and asthma.
For more information, please visit .
THERAVANCE®, the Cross/Star logo, MEDICINES THAT MAKE A DIFFERENCE® and VIBATIV® are registered trademarks of the Theravance Biopharma group of companies.
Renee Gala
Chief Financial Officer
650-808-4045
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 06.07.2016 - 20:05 Uhr
Sprache: Deutsch
News-ID 481903
Anzahl Zeichen: 0
contact information:
Town:
DUBLIN, IRELAND
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 326 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Theravance Biopharma to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference"
steht unter der journalistisch-redaktionellen Verantwortung von
Theravance Biopharma (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
